DIA Europe 2019 has ended
Back To Schedule
Thursday, February 7 • 10:45 - 11:45
#S0306: Risk Communication: New Directions for the Future

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session

Risk communication is an integral component of public health management and need to be continuously updated to meet new and developing demands. When deployed effectively, risk communication is an invaluable tool for engendering trust, protecting organizational value, and helping the public make informed decisions. Conducting risk perception research, addressing the role of trust and having a realistic outlook on the impact of risk communications are crucial considerations in risk communication evolvements for the future. This session aims at discussing implications, insights and key lessons learned from the application of risk communication principles in real-world settings, offering suggestions for risk communication research, policies and strategies.


Amelia Cupelli, MPharm


Benefit-Risk Communication: Lessons from Patients
Dinah Duarte, MSc

Evaluation of the Impact of Risk Communication on Public’s Risk Perceptions Knowledge, Attitudes, and Behaviors including Compliance (Focus groups, Surveys, and other Experiences)
Peter Mol, PhD, RPh

Risk Communication in the European Context, Building on the Best Practice Examples - Lessons from SCOPE Project
Sieta de Vries, PhD

avatar for Peter Mol

Peter Mol

Principal Clinical Assessor, University Medical Center Groningen; Member SAWP, CBG-MEB (Dutch Medicines Evaluation Board)
Peter Mol is a principal assessor at the Dutch Medicines Evaluation Board and a member (vice chair) of EMA’s Scientific Advice Working Party. He is chair of the EMA Cross-Committee Task force on Registries. He is also an assistant professor at the University Medical Center Groningen... Read More →
avatar for Dinah Duarte

Dinah Duarte

Scientific Evaluation Unit, Directorate of Medicinal Products, INFARMED, Portugal
Dr. Dinah Duarte is a senior assessor at the Scientific Evaluation Unit at the Directorate of Medicinal Products, in the Portuguese regulatory authority for medicines and health products (INFARMED). She is an expert member at the European Medicines Agency (EMA); the current Committee... Read More →
avatar for Amelia Cupelli

Amelia Cupelli

Senior Pharmacovigilance Assessor, PRAC member, AIFA
Amelia Cupelli has been in force at the Italian Medicines Agency (AIFA) since 2011 as pharmacovigilance assessor. She is a pharmacologist. Prior to joining the AIFA, she held positions for 15 years in pharmaceutical industry and as hospital pharmacist. She has participated in the... Read More →

Sieta de Vries

Post-doctoral researcher, University Medical Center Groningen
Sieta de Vries obtained her master’s degree in Social Psychology in 2010 after which she conducted her PhD-project at the University Medical Center Groningen (UMCG) in the Netherlands. She graduated in 2015 on the PhD-project with the title ‘Patient perspectives in the benefit-risk... Read More →

Thursday February 7, 2019 10:45 - 11:45 CET
E2 Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria
  03 Pharmacovigilance, Session
  • Featured Topics Pharmacovigilance
  • Tags Session